Poolbeg Pharma has just secured another key piece in its global intellectual property strategy—this time in South Korea. With patent protection for POLB 001 now extended to December 2038, the company takes a significant stride in safeguarding one of its most promising assets, reinforcing its appeal to future partners and investors.
Poolbeg Pharma has confirmed that its Immunomodulator II patent application has been officially granted by the Korean Intellectual Property Office. This protection covers POLB 001, the company’s Phase 2 ready, oral p38 MAP kinase inhibitor targeting severe influenza. The newly granted patent builds on Poolbeg’s growing intellectual property footprint and secures a critical component of its long-term strategy.
POLB 001 is more than an influenza treatment candidate. With its ability to inhibit p38 MAP kinase selectively and effectively, it is being positioned as a potential solution to a wide range of urgent medical challenges, including Cytokine Release Syndrome (CRS) triggered by cancer immunotherapies. The drug addresses not just a clinical need, but a systemic one, potentially easing pressures on healthcare infrastructure across the globe.
This patent grant in Korea reflects Poolbeg’s commitment to expanding and fortifying its IP coverage, particularly in regions where strategic partnerships and licensing opportunities could accelerate the commercial path of POLB 001. With additional patent applications already filed to extend protection against CRS and hypercytokinemia, the company is proactively reinforcing its leadership in immunomodulation.
According to CEO Dr Jeremy Skillington, the latest development significantly enhances POLB 001’s commercial value and supports the company’s broader mission of delivering transformative therapies to market. With global health concerns continuing to spotlight the need for scalable, effective treatments, Poolbeg’s forward momentum in securing IP rights across key jurisdictions sends a clear signal of long-term vision and execution.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
